In today's episode, we discuss an important alert from the WHO regarding semaglutide medicines like Ozempic, Rybelsus, and Wegovy, which are used for type 2 diabetes and weight management. A rare but serious side effect called non-arteritic anterior ischemic optic neuropathy (NAY-on), leading to sudden vision loss, has been linked to these drugs. We review what the European Medicines Agency has found, the risks involved, and what patients should do if they experience vision changes. Awareness and prompt action are crucial. Learn more about how to manage these risks while benefiting from these medications.

00:00 Introduction to Today's Episode

00:01 Understanding Semaglutide Medicines

00:17 Serious Side Effect Alert: NAY-on

00:49 Risk Assessment and Recommendations

01:45 Guidance for Patients on Semaglutide

02:19 Conclusion